LCI139

LCI139 is an in-silico designed, multitargeted small molecule kinase inhibitor developed by researchers at the Levine Cancer Institute and Wake Forest School of Medicine. It is engineered to simultaneously inhibit Phosphoinositide 3-kinase (PI3K), Cyclin-dependent kinases 4, 6, and 9 (CDK4/6/9), and Aurora kinases A and B (AURKA/B). This broad inhibitory profile is intended to overcome resistance mechanisms common to single-target agents and standard chemotherapies in non-small cell lung cancer (NSCLC). LCI139 induces both intrinsic and extrinsic apoptosis and triggers metabolic stress via the pAMPK-pFoxO3 pathway. Preclinical evaluations in patient-derived tumor organoids (PTOs) have shown significant cytotoxicity and the ability to sensitize resistant tumor models to carboplatin and other standard treatments.